Information regarding matching halt in the DiaGenic share

An important strategic focus area for DiaGenic is to supply biomarkers

for the pharmaceutical industry e.g. as presented in the Annual Report

for 2009.

Reference is made to the Annual Report for 2009 page 19: "The use of

ADtect® as a cost effective tool in clinical studies for the development

of new Alzheimer's disease medicines has been presented to major

pharmaceutical companies." An internal working document regarding one

such meeting with a leading pharmaceutical player was unfortunately made

public through a web application used by one of our advisors. The

working paper does not contain any confidential information, but

regrettably gives information concerning a meeting held with a leading

pharmaceutical company. The company has instructed our advisor not to

use this particular type of web application for work related to

DiaGenic.

Contact:

Erik Christensen MD PhD, CEO?Tel.: +47 95939918?e-mail:

AI Terminal